Keith Terada to Humans
This is a "connection" page, showing publications Keith Terada has written about Humans.
Connection Strength
0.324
-
Nagamine K, Kondo J, Kaneshiro R, Tauchi-Nishi P, Terada K. Ovarian needle aspiration in the diagnosis and management of ovarian masses. J Gynecol Oncol. 2017 Jul; 28(4):e40.
Score: 0.028
-
Terada KY, Ahn HJ, Kessel B. Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial. J Gynecol Oncol. 2016 May; 27(3):e25.
Score: 0.026
-
Terada K, Carney M, Kim R, Ahn HJ, Miyamura J. Health Disparities in Native Hawaiians and Other Pacific Islanders Following Hysterectomy for Endometrial Cancer. Hawaii J Med Public Health. 2016 05; 75(5):137-9.
Score: 0.026
-
Lai T, Kessel B, Ahn HJ, Terada KY. Ovarian cancer screening in menopausal females with a family history of breast or ovarian cancer. J Gynecol Oncol. 2016 Jul; 27(4):e41.
Score: 0.026
-
Vierkoetter KR, Kagami LA, Ahn HJ, Shimizu DM, Terada KY. Loss of Mismatch Repair Protein Expression in Unselected Endometrial Adenocarcinoma Precursor Lesions. Int J Gynecol Cancer. 2016 Feb; 26(2):228-32.
Score: 0.025
-
Terada KY, Elia J, Kim R, Carney M, Ahn HJ. Abnormal CA-125 levels in menopausal women without ovarian cancer. Gynecol Oncol. 2014 Oct; 135(1):34-7.
Score: 0.023
-
Vierkoetter KR, Ayabe AR, VanDrunen M, Ahn HJ, Shimizu DM, Terada KY. Lynch Syndrome in patients with clear cell and endometrioid cancers of the ovary. Gynecol Oncol. 2014 Oct; 135(1):81-4.
Score: 0.023
-
Terada KY, Black M, Terada LH, Davis J, Shimizu DM. Survival of endometrial cancer patients with lymphatic invasion and deficient mismatch repair expression. Gynecol Oncol. 2013 Apr; 129(1):188-92.
Score: 0.021
-
Grzankowski KS, Shimizu DM, Kimata C, Black M, Terada KY. Clinical and pathologic features of young endometrial cancer patients with loss of mismatch repair expression. Gynecol Oncol. 2012 Sep; 126(3):408-12.
Score: 0.020
-
Hakim AA, Terada KY. Sentinel node dissection in vulvar cancer. Curr Treat Options Oncol. 2006 Mar; 7(2):85-91.
Score: 0.013
-
Terada KY, Shimizu DM, Jiang CS, Wong JH. Outcomes for patients with T1 squamous cell cancer of the vulva undergoing sentinel node biopsy. Gynecol Oncol. 2006 Aug; 102(2):200-3.
Score: 0.013
-
Terada K, Mattson D, Goo D, Shimizu D. DNA aneuploidy is associated with increased mortality for stage I endometrial cancer. Gynecol Oncol. 2004 Dec; 95(3):483-7.
Score: 0.012
-
Randall ME, Filiaci V, McMeekin DS, von Gruenigen V, Huang H, Yashar CM, Mannel RS, Kim JW, Salani R, DiSilvestro PA, Burke JJ, Rutherford T, Spirtos NM, Terada K, Anderson PR, Brewster WR, Small W, Aghajanian CA, Miller DS. Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer. J Clin Oncol. 2019 07 20; 37(21):1810-1818.
Score: 0.008
-
Clinton LK, Kondo J, Carney ME, Tauchi-Nishi P, Terada K, Shimizu D. Low-Volume Lymph Node Metastases in Endometrial Carcinoma. Int J Gynecol Cancer. 2017 07; 27(6):1165-1170.
Score: 0.007
-
Sagata D, Minagawa I, Kohriki H, Pitia AM, Uera N, Katakura Y, Sukigara H, Terada K, Shibata M, Park EY, Hasegawa Y, Sasada H, Kohsaka T. The insulin-like factor 3 (INSL3)-receptor (RXFP2) network functions as a germ cell survival/anti-apoptotic factor in boar testes. Endocrinology. 2015 Apr; 156(4):1523-39.
Score: 0.006
-
Kojima G, Terada KY, Miki N, Miki K. Non-islet cell tumor hypoglycemia associated with recurrent carcinosarcoma of the ovary. Endocr Pract. 2013 Jul-Aug; 19(4):e83-7.
Score: 0.005
-
Lurie G, Gaudet MM, Spurdle AB, Carney ME, Wilkens LR, Yang HP, Weiss NS, Webb PM, Thompson PJ, Terada K, Setiawan VW, Rebbeck TR, Prescott J, Orlow I, O'Mara T, Olson SH, Narod SA, Matsuno RK, Lissowska J, Liang X, Levine DA, Le Marchand L, Kolonel LN, Henderson BE, Garcia-Closas M, Doherty JA, De Vivo I, Chen C, Brinton LA, Akbari MR, Goodman MT. The obesity-associated polymorphisms FTO rs9939609 and MC4R rs17782313 and endometrial cancer risk in non-Hispanic white women. PLoS One. 2011 Feb 08; 6(2):e16756.
Score: 0.005
-
Palmieri RT, Wilson MA, Iversen ES, Clyde MA, Calingaert B, Moorman PG, Poole C, Anderson AR, Anderson S, Anton-Culver H, Beesley J, Hogdall E, Brewster W, Carney ME, Chen X, Chenevix-Trench G, Chang-Claude J, Cunningham JM, Dicioccio RA, Doherty JA, Easton DF, Edlund CK, Gayther SA, Gentry-Maharaj A, Goode EL, Goodman MT, Kjaer SK, Hogdall CK, Hopkins MP, Jenison EL, Blaakaer J, Lurie G, McGuire V, Menon U, Moysich KB, Ness RB, Pearce CL, Pharoah PD, Pike MC, Ramus SJ, Rossing MA, Song H, Terada KY, Vandenberg D, Vierkant RA, Wang-Gohrke S, Webb PM, Whittemore AS, Wu AH, Ziogas A, Berchuck A, Schildkraut JM. Polymorphism in the IL18 gene and epithelial ovarian cancer in non-Hispanic white women. Cancer Epidemiol Biomarkers Prev. 2008 Dec; 17(12):3567-72.
Score: 0.004
-
Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY, Goodman MT. Genetic polymorphisms in the estrogen receptor beta (ESR2) gene and the risk of epithelial ovarian carcinoma. Cancer Causes Control. 2009 Feb; 20(1):47-55.
Score: 0.004
-
Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY, Goodman MT. Genetic polymorphisms in the Paraoxonase 1 gene and risk of ovarian epithelial carcinoma. Cancer Epidemiol Biomarkers Prev. 2008 Aug; 17(8):2070-7.
Score: 0.004
-
Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY, Goodman MT. Combined oral contraceptive use and epithelial ovarian cancer risk: time-related effects. Epidemiology. 2008 Mar; 19(2):237-43.
Score: 0.004
-
Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY, Goodman MT. Vitamin D receptor gene polymorphisms and epithelial ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 2007 Dec; 16(12):2566-71.
Score: 0.004
-
Lurie G, Thompson P, McDuffie KE, Carney ME, Terada KY, Goodman MT. Association of estrogen and progestin potency of oral contraceptives with ovarian carcinoma risk. Obstet Gynecol. 2007 Mar; 109(3):597-607.
Score: 0.003
-
Tung KH, Wilkens LR, Wu AH, McDuffie K, Nomura AM, Kolonel LN, Terada KY, Goodman MT. Effect of anovulation factors on pre- and postmenopausal ovarian cancer risk: revisiting the incessant ovulation hypothesis. Am J Epidemiol. 2005 Feb 15; 161(4):321-9.
Score: 0.003
-
Bushley AW, Ferrell R, McDuffie K, Terada KY, Carney ME, Thompson PJ, Wilkens LR, Tung KH, Ness RB, Goodman MT. Polymorphisms of interleukin (IL)-1alpha, IL-1beta, IL-6, IL-10, and IL-18 and the risk of ovarian cancer. Gynecol Oncol. 2004 Dec; 95(3):672-9.
Score: 0.003
-
Tung KH, Goodman MT, Wu AH, McDuffie K, Wilkens LR, Kolonel LN, Nomura AM, Terada KY, Carney ME, Sobin LH. Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study. Am J Epidemiol. 2003 Oct 01; 158(7):629-38.
Score: 0.003
-
Goodman MT, Wu AH, Tung KH, McDuffie K, Cramer DW, Wilkens LR, Terada K, Reichardt JK, Ng WG. Association of galactose-1-phosphate uridyltransferase activity and N314D genotype with the risk of ovarian cancer. Am J Epidemiol. 2002 Oct 15; 156(8):693-701.
Score: 0.003
-
Hawes D, Liu PY, Muggia FM, Wilczynski S, Cote R, Felix J, Terada K, Belt RJ, Alberts DS. Correlation of p53 immunostaining in primary and residual ovarian cancer at the time of positive second-look laparotomy and its prognostic role: a Southwest Oncology Group ancillary study. Gynecol Oncol. 2002 Oct; 87(1):17-23.
Score: 0.003
-
Goodman MT, Wu AH, Tung KH, McDuffie K, Kolonel LN, Nomura AM, Terada K, Wilkens LR, Murphy S, Hankin JH. Association of dairy products, lactose, and calcium with the risk of ovarian cancer. Am J Epidemiol. 2002 Jul 15; 156(2):148-57.
Score: 0.002